1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Complicated Intra-Abdominal Infections Global Clinical Trials Review, H2, 2014

Complicated Intra-Abdominal Infections Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, “Complicated Intra-Abdominal Infections Global Clinical Trials Review, H2, 2014" provides data on the Complicated Intra-Abdominal Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Complicated Intra-Abdominal Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Complicated Intra-Abdominal Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Complicated Intra-Abdominal Infections Global Clinical Trials Review, H2, 2014
Table of Contents

Introduction 6
Complicated Intra-Abdominal Infections 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Complicated Intra-Abdominal Infections to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Complicated Intra-Abdominal Infections to Infectious Disease Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Complicated Intra-Abdominal Infections 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Complicated Intra-Abdominal Infections Therapeutics Clinical Trials 29
Prominent Drugs 31
Latest Clinical Trials News on Complicated Intra-Abdominal Infections 32
Aug 19, 2014: Actavis Announces Positive Topline Results From The Phase III Program Of Ceftazidime-Avibactam In Patients With Complicated Intra-Abdominal Infections(cIAI) 32
Clinical Trial Profiles 33
Clinical Trial Overview of Top Companies 33
Pfizer Inc. 33
Clinical Trial Overview of Pfizer Inc. 33
Merck and Co., Inc. 35
Clinical Trial Overview of Merck and Co., Inc. 35
AstraZeneca PLC 36
Clinical Trial Overview of AstraZeneca PLC 36
Tetraphase Pharmaceuticals Inc. 37
Clinical Trial Overview of Tetraphase Pharmaceuticals Inc. 37
Bayer AG 38
Clinical Trial Overview of Bayer AG 38
Janssen Pharmaceuticals, Inc. 39
Clinical Trial Overview of Janssen Pharmaceuticals, Inc. 39
Cubist Pharmaceuticals, Inc. 40
Clinical Trial Overview of Cubist Pharmaceuticals, Inc. 40
Johnson and Johnson 41
Clinical Trial Overview of Johnson and Johnson 41
Daiichi Sankyo Company, Limited 42
Clinical Trial Overview of Daiichi Sankyo Company, Limited 42
Clinical Trial Overview of Top Institutes / Government 43
Tartu University Hospital 43
Clinical Trial Overview of Tartu University Hospital 43
Lausanne University Hospital 44
Clinical Trial Overview of Lausanne University Hospital 44
Duke University Medical Center 45
Clinical Trial Overview of Duke University Medical Center 45
Kaohsiung Medical University Chung-Ho Memorial Hospital 46
Clinical Trial Overview of Kaohsiung Medical University Chung-Ho Memorial Hospital 46
Universita di Bologna 47
Clinical Trial Overview of Universita di Bologna 47
Eunice Kennedy Shriver National Institute of Child Health and Human Development 48
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 48
Akershus University Hospital 49
Clinical Trial Overview of Akershus University Hospital 49
Five Key Clinical Profiles 50
Appendix 105
Abbreviations 105
Definitions 105
Research Methodology 106
Secondary Research 106
About GlobalData 107
Contact Us 107
Disclaimer 107
Source 107

List of Tables

Complicated Intra-Abdominal Infections Therapeutics, Global, Clinical Trials by Region, 2014* 7
Complicated Intra-Abdominal Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Complicated Intra-Abdominal Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Complicated Intra-Abdominal Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Complicated Intra-Abdominal Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Complicated Intra-Abdominal Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Complicated Intra-Abdominal Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Complicated Intra-Abdominal Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Complicated Intra-Abdominal Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Complicated Intra-Abdominal Infections Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Complicated Intra-Abdominal Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Complicated Intra-Abdominal Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Complicated Intra-Abdominal Infections Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Complicated Intra-Abdominal Infections Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Complicated Intra-Abdominal Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 33
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 35
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 36
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Tetraphase Pharmaceuticals Inc., 2014* 37
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 38
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Janssen Pharmaceuticals, Inc., 2014* 39
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Cubist Pharmaceuticals, Inc., 2014* 40
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson and Johnson, 2014* 41
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2014* 42
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Tartu University Hospital, 2014* 43
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Lausanne University Hospital, 2014* 44
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University Medical Center, 2014* 45
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Kaohsiung Medical University Chung-Ho Memorial Hospital, 2014* 46
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Universita di Bologna, 2014* 47
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014* 48
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Akershus University Hospital, 2014* 49

List of Figures

Complicated Intra-Abdominal Infections Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Complicated Intra-Abdominal Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Complicated Intra-Abdominal Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Complicated Intra-Abdominal Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Complicated Intra-Abdominal Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Complicated Intra-Abdominal Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Complicated Intra-Abdominal Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Complicated Intra-Abdominal Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Complicated Intra-Abdominal Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Complicated Intra-Abdominal Infections Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Complicated Intra-Abdominal Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Complicated Intra-Abdominal Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Complicated Intra-Abdominal Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Complicated Intra-Abdominal Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
GlobalData Methodology 106

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: Kol Insight

September 2016 $ 8085

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy Market in Europe

  • November 2016
    19 pages
  • Therapy  

  • Europe  

View report >

Therapy Market and Hypertension Statistics in Asia and the US

  • November 2016
    26 pages
  • Therapy  

    Hypertension  

    Cardiovascular ...  

  • Asia  

    United States  

    Europe  

View report >

Therapy Market in the US - Forecast

  • November 2016
    6 pages
  • Therapy  

    Opioid  

  • United States  

View report >

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.